News

A recently granted patent (Publication Number: US11912759B2) discloses an antibody designed to bind to human transthyretin. The antibody comprises specific amino…

https://www.oneamyloidosisvoice.com/wp-content/uploads/2024/03/Full-Article-hATTR-Holistic-Care-Con…

"Light the Night for Amyloidosis" is an Amyloidosis Foundation awareness campaign created to draw attention to amyloidosis symptoms, diagnosis, treatment and…

The transthyretin amyloidosis market size is projected to grow significantly during the forecast period (2023–2032) owing to the currently approved drugs, along…

When: Saturday, October 21st, 2023 9:00 am - 2:00 pm Where: Huntsman Cancer Hospital Salt Lake City, Utah In-Person and Virtual Registration Options Available…

On behalf of the Organizing Committee, it is our great pleasure to host the 3rd Utah Amyloidosis Symposium in Salt Lake City, Utah. The 2023 symposium will be held…

When: Sunday, October 15, 2023 | 8:00am-3:00pm Where: Hale Cafe Atrium Brigham & Women's Hospital 60 Fenwood Road 1st Floor Boston, MA 02115 Guests:…

When: Saturday, September 30, 2023 | 9:00am-3:00pm Where: UNC Medical Center Sanofi Conference Room, First Floor 101 Manning Drive Chapel Hill, NC 27514 Guests:…

This Meeting Is for AL Amyloidosis Only When: Saturday, September 9, 2023 | 9:00 am - 2:00 pm Registration: 8:00 am - 9:00 am Meeting: 9:00 - 2:00 pm Lunch: 12:00…

The 30-month results of the phase 3 ATTRibute-CM trial provide the latest insight into the effects of acoramidis in people with transthyretin amyloid cardiomyopathy…